摘要
目的:观察加巴喷丁和卡马西平治疗原发性三叉神经痛的临床疗效及安全性。方法:原发性三叉神经痛患者91例,采用双盲、随机对照,分为加巴喷丁组(n=46)和卡马西平组(n=45)。采用视觉模拟评分(VAS)评估患者用药前和用药后1、2、4周疼痛程度,同时观察患者的不良反应,并记录治疗前后血、尿常规和肝、肾功能等指标。结果:卡马西平组患者,与用药前VAS值[(72.80±7.58)mm]相比,用药后VAS值显著下降(P<0.01),加巴喷丁组患者,与用药前VAS值[(73.55±6.77)mm]相比,用药后VAS值也显著下降(P<0.01),用药后1、2、4周两组同时间的VAS差异无显著性。用药后1、2、4周两组同时间有效率差异无显著性。不良反应在加巴喷丁组(30.43%)低于卡马西平组(60.87%),两组有显著性差异(P<0.01)。结论:加巴喷丁治疗和卡马西平治疗原发性三叉神经痛是有效而安全的,加巴喷丁安全性优于卡马西平。
Objective：To study the efficacy and safety of Gabapentin and Carbamazepine in the treatment of primary trigeminal neuralgia.Methods：Ninety one patients with PTN were double blindly controlled trial and randomly allocated into two groups,group A（gabapentin,n=46） and group B（carbamazepine n=45）.The quantification of severity of pain was done using visual analogue scale（VAS） at the beginning of the study and after 1 week,2 weeks,and 4 weeks.Adverse reactions were also observed.Detailed biochemical investigations,including routine blood and urine examination,liver and renal function tests were done at the beginning and at the end of the study.Results：After 4 weeks treatment with gabapentin and Carbamazepine,there was significant reduction in pain in two groups compared with that of before treatment.1,2,4,weeks of post-therapy,VAS in the two groups showed not significantly differentce from each other（P〉0.05） and there was no significant difference of improvement between these two groups（P〉0.05）.The ratio of adverse reaction in gabapentin group（30.43%） was significant lower than that in Carbamazepine group（60.87%）（P〈0.01）.Conclusion：Gabapentin and Carbamazepine provided significant pain relief in patients of PTN.The security of gabapentin was better than that of Carbamazepine.
出处
《华西医学》
CAS
2008年第4期790-792,共3页
West China Medical Journal
关键词
加巴喷丁
卡马西平
原发性三叉神经痛
疗效
不良反应
gabapentin
carbamazepine
primary trigeminal neuralgia
effectiveness
adverse reactions
